KAPA (STOCKS)
Kairos Pharma, Ltd.
$0.630000
+0.030500 (+5.09%)
Prev close: $0.599500
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- John S. Yu
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $12.85M
- Employees
- 4
- P/E (TTM)
- -1.98
- P/B (TTM)
- 1.63
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.07 | $-0.05 | -0.0156 | -28.68% |
|
Sep 2025 (Q3)
|
$-0.07 | $-0.07 | -0.0020 | -2.94% |
|
Jun 2025 (Q2)
|
$-0.08 | $-0.06 | -0.0239 | -42.60% |
|
Mar 2025 (Q1)
|
$-0.08 | $-0.05 | -0.0290 | -56.86% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $125.00K |
| Operating Expenses | $5.57M |
| Research and Development | $2.14M |
| Other Operating Expenses | $3.44M |
| Operating Income/Loss | -$5.57M |
| Income/Loss From Continuing Operations After Tax | -$5.45M |
| Income/Loss From Continuing Operations Before Tax | -$5.45M |
| Net Income/Loss | -$5.45M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$5.45M |
| Net Income/Loss Available To Common Stockholders, Basic | -$5.45M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.30 |
| Diluted Earnings Per Share | -$0.30 |
| Basic Average Shares | 18,427,787 |
| Diluted Average Shares | 18,427,787 |
| Assets | $6.54M |
| Current Assets | $5.39M |
| Noncurrent Assets | $1.15M |
| Intangible Assets | $62.00K |
| Other Non-current Assets | $1.09M |
| Liabilities | $199.00K |
| Current Liabilities | $199.00K |
| Noncurrent Liabilities | $0.00 |
| Equity | $6.34M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $6.34M |
| Liabilities And Equity | $6.54M |
| Net Cash Flow From Operating Activities | -$3.44M |
| Net Cash Flow From Operating Activities, Continuing | -$3.44M |
| Net Cash Flow From Investing Activities | -$3.22M |
| Net Cash Flow From Investing Activities, Continuing | -$3.22M |
| Net Cash Flow From Financing Activities | $6.66M |
| Net Cash Flow From Financing Activities, Continuing | $6.66M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$5.45M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$5.45M |
| Other Comprehensive Income/Loss | $0.00 |